Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
valuation ratios | |
---|---|
pe ratio | -4.75 |
peg ratio | -0.17 |
price to book ratio | 1.47 |
price to sales ratio | 12.79 |
enterprise value multiple | -6.68 |
price fair value | 1.47 |
profitability ratios | |
---|---|
gross profit margin | 90.99% |
operating profit margin | -260.7% |
pretax profit margin | -229.91% |
net profit margin | -230.66% |
return on assets | -20.82% |
return on equity | -29.91% |
return on capital employed | -27.47% |
liquidity ratio | |
---|---|
current ratio | 2.48 |
quick ratio | 2.48 |
cash ratio | 2.00 |
efficiency ratio | |
---|---|
days of inventory outstanding | 0.00 |
operating cycle | 16.95 |
days of payables outstanding | 742.54 |
cash conversion cycle | -725.58 |
receivables turnover | 21.53 |
payables turnover | 0.49 |
inventory turnover | 0.00 |
debt and solvency ratios | |
---|---|
debt ratio | 0.00 |
debt equity ratio | 0.00 |
long term debt to capitalization | 0.00 |
total debt to capitalization | 0.00 |
interest coverage | -52.25 |
cash flow to debt ratio | 0.00 |
cash flow ratios | |
---|---|
free cash flow per share | -0.12 |
cash per share | 0.17 |
operating cash flow per share | -0.12 |
free cash flow operating cash flow ratio | 1.00 |
cash flow coverage ratios | 0.00 |
short term coverage ratios | 0.00 |
capital expenditure coverage ratio | -250.16 |
Frequently Asked Questions
Lineage Cell Therapeutics, Inc. (LCTX) published its most recent earnings results on 14-11-2024.
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Lineage Cell Therapeutics, Inc. (AMEX:LCTX)'s trailing twelve months ROE is -29.91%.
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Lineage Cell Therapeutics, Inc. (LCTX) currently has a ROA of -20.82%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
LCTX reported a profit margin of -230.66% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.48 in the most recent quarter. The quick ratio stood at 2.48, with a Debt/Eq ratio of 0.00.